FOLH1 and neoplasm: Therefore, a tumour uptake of [18F]F-DCFPyL above the liver background, like using [68Ga]Ga-PSMA-11, can be considered as equally suitable for defining PSMA-positivity by a semiquantitative assessment based on the liver background, e.g. prior to radioligand therapy with 177Lu-labelled PSMA ligands.